United States · Markets & Finance · Morningstar

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer

Published by Morningstar · United States 12 h ago

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical data on its Nectin-4-targeting…

Read the full article on Morningstar Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.morningstar.com)

Also worth reading

Business Insider

Ukraine is making anti-Shahed missiles that have to cost less than $20,000 per shot

Cointelegraph

Zoom adds ‘proof of human’ badges to show you’re not a deepfake

CNBC

Japanese Prime Minister Takaichi rejects criticism around weak yen and high interest rates

OilPrice.com

Oil Prices Slip as Trump-Putin Diesel Deal Raises Supply Hopes

CoinDesk

Zcash developers plan a fix to keep ZEC swaps private from future quantum computers

Fortune